EyePoint shares tumble after Phase III eye drug fails to meet endpoints
EyePoint Pharmaceuticals' stock fell sharply on Monday following the announcement that its late-stage Duravyu trial did not achieve its primary goals.
EyePoint Pharmaceuticals' shares dropped sharply on Monday after the company disclosed that Duravyu, its experimental treatment for an eye disease, failed to meet primary endpoints in a Phase III trial. The setback triggered a sell-off in the stock, reflecting investor concerns over the drug's commercial prospects. No further clinical data were released, and the company has not indicated whether it will pursue additional studies or adjust its development strategy.
The announcement came without detailed commentary from company executives, and analysts noted that the negative result could delay or diminish future revenue expectations for the biotech firm.